Andere Sprachen Aclarion, Inc.

Aktien

A3EYAA

US6551872012

ACON

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
0,2859 ^USD	-4,38 %		+1,28 %	-91,07 %

25.06.	Aclarion weitet kommerzielles Engagement mit der London Clinic aus, um den Zugang zu Nociscan im gesamten Großraum London zu erweitern	CI
15.05.	Aclarion, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aclarion : AXA is the 2nd largest provider of private medical insurance in the UK. Payer coverage is the most important catalyst Aclarion can achieve to drive volume and revenue. AXA represents the first insurance company to approve payment for Nociscan Form 8 K	26.06.
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK	26.06.
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London	25.06.
Aclarion Expands Commercial Engagement with the London Clinic to Grow Access to Nociscan Throughout Greater London	25.06.
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution	20.06.
Aclarion : Certificate of Incorporation/Bylaws Form 8 K	19.06.
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution	18.06.
Certain Warrants of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26.05.
Certain Stock Options of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26.05.
Certain Common Stock of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26.05.
Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain	25.04.
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs	04.03.
Aclarion Announces Closing of $3.0 Million Public Offering	27.02.
Top Midday Decliners	26.02.
Aclarion Announces Pricing of $3.0 Million Public Offering	26.02.
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.02.
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership	05.02.
Top Premarket Decliners	02.02.
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast	26.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aclarion, Inc.

Aktien

A3EYAA

US6551872012

ACON

Andere Sprachen

Filter